Please login to the form below

Not currently logged in
Email:
Password:

Milestone names chief medical officer

Francis Plat bring experience from Merck, Daiichi-Sankyo, Novartis and BMS to the role

Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer.

Dr Plat joins from Merck & Co where he was head of atherosclerosis and cardiovascular at the company's Merck Research Laboratories division.

His other big pharma experience includes roles at Daiichi-Sankyo, Novartis, and Bristol Myers Squibb, working on cardiovascular products including Efient, Diovan and Approvel.

As chief medical officer Dr Plat's responsibilities will include heading up the development of the company's lead product MSP-2017, which is under investigation as a treatment for paroxysmal supraventricular tachycardia – a condition defined by episodes of rapid heart rate.

Dr Plat commented that MSP-2017 promises a “paradigm shift” in the treatment of paroxysmal supraventricular tachycardia as it allows patients a far improved quality of life.

Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program given his extensive cardiovascular drug development expertise developed during his career in large pharmaceutical companies."

28th July 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics